ADMA Biologics Inc vs Ford Motor Company — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Ford Motor Company trades at $13.85 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 25.1× ADMA Biologics Inc's market cap, and Ford Motor Company pays a 4.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | F | |
|---|---|---|
Market Cap | $2.22B | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $17.44 |
52-Week Low | $7.60 | $11.21 |
Enterprise Value | $2.29B | $187.71B |
Dividend Yield | — | 4.29% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Ford (F) trades at $13.86, down 1.14%, with a bearish technical signal. Recent earnings show volatility, with Q1 and Q2 2026 beats but a Q4 2025 miss. The company reported a net loss of $8.18B for 2025, though operating cash flow remains strong at $21.28B. News highlights the upcoming affordable Fathom EV truck priced at $28,350, targeting market share gains amid high vehicle prices.
The outlook is mixed: analyst consensus is a Buy with a $16.18 target, offering potential upside, but risks include intense EV competition, profitability challenges, and high debt levels. The stock's low P/E of 11.84 may attract value investors, but execution on new models is critical for recovery.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →